SCHEMBL754904

SCHEMBL754904

COC(=O)c1ccc(-c2ccc([C@H](C)[C@](O)(c3ccc(=O)n(C)c3)C(F)(F)F)c(Cl)c2)cc1OC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.36
LMNA P02545 3/20 0.36
HPGD P15428 3/20 0.36
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 2/20 0.36
NPY1R P25929 1/20 0.36
NPY2R P49146 1/20 0.36
RAB9A P51151 1/20 0.36
CHEK1 O14757 1/20 0.35
HTT P42858 1/20 0.35
THRB P10828 1/20 0.34
PIK3CA P42336 1/20 0.34
GAA P10253 2/20 0.33
BAZ2B Q9UIF8 1/20 0.32
BAZ2A Q9UIF9 1/20 0.32
ROCK2 O75116 1/20 0.32
ROCK1 Q13464 1/20 0.32
MRGPRX4 Q96LA9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL734838 1.00 PDK2 (0.36) PDK2LMNAHPGDKDM4EALDH1A1
SCHEMBL754457 0.93 PDK2 (0.40) PDK2LMNAKDM4EGAABAZ2B
SCHEMBL733268 0.93 PDK2 (0.40) PDK2LMNAKDM4EGAABAZ2B
SCHEMBL733422 0.92 ESR1 (0.35) HPGDKDM4EALDH1A1CHEK1AKR1C3
SCHEMBL755590 0.92 ESR1 (0.35) HPGDKDM4EALDH1A1CHEK1AKR1C3
SCHEMBL752282 0.90 KDM4E (0.36) PDK2KDM4EBAZ2BBAZ2AMRGPRX4
SCHEMBL732326 0.90 KDM4E (0.36) PDK2KDM4EBAZ2BBAZ2AMRGPRX4
SCHEMBL753068 0.90 KMT2A (0.35) PDK2LMNAHPGDKDM4EALDH1A1
SCHEMBL733375 0.90 KMT2A (0.35) PDK2LMNAHPGDKDM4EALDH1A1
SCHEMBL15789742 0.88 KMT2A (0.33) LMNASMN1; SMN2MAPTTHRBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
WO-2010108902-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, CRHR1 PDK2 936/4885LMNA 1995/4885HPGD 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.